-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Nanjing · Big coffee gathered in May2021 nucleic acid drug development forum announced schedule ★ May Nanjing2021 nucleic acid drug development forum is about to open May 3, 2021 / Yimaike news eMedClub News/-April On the 23rd, Avillion announced the Phase 2 clinical results of its trispecific nanobody Sonelokimab (M1095) in plaque psoriasis on THE LANCET (The Lancet).
All primary and secondary endpoints reached the target.
Sonelokimab (also known as M1095) is a three-specific half-life extended nanobody that can neutralize IL-17A and IL-17F, and has the potential to treat inflammatory diseases.
Due to the small size and unique structure of Nanobodies®, they may become ideal building blocks for a new generation of new biopharmaceuticals.
In 2013, Germany's Merck AG obtained the complete exclusive right of anti-IL-17 A/F nanobody through a global development and commercialization transaction with Ablynx.
Avillion and Merck AG of Germany signed a cooperative development agreement in Darmstadt in March 2017 for the development of the second and third phases of sonelokimab.
Psoriasis is a chronic recurrent inflammatory skin disease that affects approximately 8 million people in the United States and 125 million globally.
According to the World Psoriasis Day Association, 2-3% of the total population suffers from psoriasis.
At present, the cause of psoriasis is not clear, and it may be related to genetic factors.
The disease can occur at any age.
There is no particularly good treatment method, so the patient may need life-long treatment.
The interleukin (IL)-17 cytokine family consists of six members (IL-17 A–F).
The current concept is that both IL-17A and IL-17F are up-regulated in psoriasis and have biological activity as dimers (IL-17A/A, IL-17A/F and IL-17F/F).
The IL-17 receptor A chain (IL-17RA) and a receptor composed of IL-17 signal the receptor C chain.
A monoclonal antibody targeting IL-17 is an effective treatment for plaque psoriasis.
Compared with IL-17A inhibition alone, the dual neutralization of IL-17A and IL-17F in vitro leads to greater inflammation inhibition.
Early clinical studies have shown the benefits of this method.
Recommended reading: NIH research team isolated a new coronavirus nanobody that also has a blocking effect on the high-affinity variant S protein Yimaihei Technology makes breakthrough progress in the world's first inhaled new coronavirus neutralizing nanobody drug 2021 nucleic acid drug development forum It will kick off in Nanjing from May 7th to 8th, 2021, to welcome the "new era of super drugs",
All primary and secondary endpoints reached the target.
Sonelokimab (also known as M1095) is a three-specific half-life extended nanobody that can neutralize IL-17A and IL-17F, and has the potential to treat inflammatory diseases.
Due to the small size and unique structure of Nanobodies®, they may become ideal building blocks for a new generation of new biopharmaceuticals.
In 2013, Germany's Merck AG obtained the complete exclusive right of anti-IL-17 A/F nanobody through a global development and commercialization transaction with Ablynx.
Avillion and Merck AG of Germany signed a cooperative development agreement in Darmstadt in March 2017 for the development of the second and third phases of sonelokimab.
Psoriasis is a chronic recurrent inflammatory skin disease that affects approximately 8 million people in the United States and 125 million globally.
According to the World Psoriasis Day Association, 2-3% of the total population suffers from psoriasis.
At present, the cause of psoriasis is not clear, and it may be related to genetic factors.
The disease can occur at any age.
There is no particularly good treatment method, so the patient may need life-long treatment.
The interleukin (IL)-17 cytokine family consists of six members (IL-17 A–F).
The current concept is that both IL-17A and IL-17F are up-regulated in psoriasis and have biological activity as dimers (IL-17A/A, IL-17A/F and IL-17F/F).
The IL-17 receptor A chain (IL-17RA) and a receptor composed of IL-17 signal the receptor C chain.
A monoclonal antibody targeting IL-17 is an effective treatment for plaque psoriasis.
Compared with IL-17A inhibition alone, the dual neutralization of IL-17A and IL-17F in vitro leads to greater inflammation inhibition.
Early clinical studies have shown the benefits of this method.
Recommended reading: NIH research team isolated a new coronavirus nanobody that also has a blocking effect on the high-affinity variant S protein Yimaihei Technology makes breakthrough progress in the world's first inhaled new coronavirus neutralizing nanobody drug 2021 nucleic acid drug development forum It will kick off in Nanjing from May 7th to 8th, 2021, to welcome the "new era of super drugs",
